PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: Among ovarian cancer patients with BRCA mutation or homologous recombination deficiency (HRD), the efficacy of PARP inhibitors has been proven, and BRCA mutation and HRD are currently indicated for PARP inhibitor maintenance treatment.